Jose Hernandez, MD
Family Medicine · Conway, SCNPI 1255561627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $318 and has fallen 58.6% since, to $132 in 2025.
Across 54 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$179
- Indivior Inc.$171
- Astellas Pharma US Inc$151
- AstraZeneca$110
- Novo Nordisk$95
- Daiichi Sankyo Inc.$85
- plus $462 from 15 others
Across 3 payments — averaging $9879.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$30K
What the payments were for
- Food & beverage$1,23498%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $179 |
| Indivior Inc. | 6 | $171 |
| Astellas Pharma US Inc | 4 | $151 |
| AstraZeneca | 7 | $110 |
| Novo Nordisk | 5 | $95 |
| Daiichi Sankyo Inc. | 4 | $85 |
| Ardelyx, Inc. | 4 | $70 |
| AbbVie | 4 | $70 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Abbott | 3 | $46 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Pfizer | 2 | $33 |
| Viiv Healthcare Company | 1 | $30 |
| Braeburn Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,253 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $120,850 |
| OzempicSemaglutide | 57 | $86,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $78,973 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $62,153 |
| FarxigaDapagliflozin Propanediol | 47 | $57,575 |
| JardianceEmpagliflozin | 22 | $24,676 |
| RybelsusSemaglutide | 15 | $24,345 |
| MounjaroTirzepatide | 16 | $24,334 |
| JanuviaSitagliptin Phosphate | 15 | $22,977 |
| XareltoRivaroxaban | 21 | $21,824 |
| WegovySemaglutide | 17 | $21,579 |
| Spiriva RespimatTiotropium Bromide | 21 | $20,918 |
| LinzessLinaclotide | 19 | $17,282 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 345 | $14,735 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $95 | $131,97789 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere | $110 | $124,281122 claims |
| PfizerEliquis | $33 | $120,850124 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Shingrix | $14 | $111,120134 claims |
| Lilly USA, LLCMounjaro | $13 | $24,33416 claims |
| AbbVieLinzess | $70 | $17,28219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Conway
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
- Nicholas PenningsNorth Myrtle Beach$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.